Taysha Gene Therapies (TSHA) Operating Income (2020 - 2026)

Taysha Gene Therapies has reported Operating Income for 7 years, with the latest figure at -$43.5 million in Q1 2026.

• Quarterly Operating Income fell 103.01% year-over-year to -$43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132.6 million (down 49.7% YoY) and the FY2025 annual result came in at -$110.5 million, down 20.82% from the prior year.
• Operating Income slipped to -$43.5 million in Q1 2026 per TSHA's latest filing, from -$28.3 million in the prior quarter.
• Over five years, Operating Income peaked at -$16.2 million in Q4 2023 and troughed at -$54.0 million in Q4 2022.
• A 5-year average of -$28.3 million and a median of -$25.5 million in 2022 frame the typical range for Operating Income.
• The sharpest annual moves came in 2023 and 2026: Operating Income surged 69.9% in 2023, then tumbled 103.01% in 2026.
• Over 5 years, Operating Income stood at -$54.0 million in 2022, then surged by 69.9% to -$16.2 million in 2023, then declined by 22.69% to -$19.9 million in 2024, then tumbled by 41.98% to -$28.3 million in 2025, then slumped by 53.66% to -$43.5 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$43.5 million, -$28.3 million, and -$34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.